Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 16Vincristine 12Prednisone 11Methotrexate 11Etoposide 9Cytarabine 9merphos 8blinatumomab 8venetoclax 7prednylidene 7pegaspargase 7deltacortene 7Specimen Handling 7Mercaptopurine 7Dexamethasone 7azathiopurine 6N,N-dicyclohexyl-isoborneol-10-sulfonamide 6Doxorubicin 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5Spinal Puncture 5Rituximab 5Leucovorin 5Biopsy 5fludarabine phosphate 4Stem Cell Transplantation 4Methylprednisolone 4Inotuzumab Ozogamicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Burkitt Lymphoma × Leyk × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡